

Supplementary

Table S1 Survival (PFS and OS) curve comparisons of Filipinos patients with NSCLC harboring different EGFR mutations and different levels of PD-L1 expressions

Patient groups	mPFS (95% CI), days	P value	mOS (95% CI), days	P value
Exon19del/PD-L1 (+)	392 (253 to 874)	0.0096	NR	0.1199
Exon19del/PD-L1 (-)	NR		NR	
Exon21L858R/PD-L1 (+)	311 (104 to 311)		NR	
Exon21L858R/PD-L1 (-)	163 (37 to 187)		369 (51 to 369)	
Exon19del/neg PD-L1 TPS	NR	0.4727	NR	0.2231
Exon19del/low PD-L1 TPS	392 (322 to 392)		NR	
Exon19del/high PD-L1 TPS	477.5 (253 to 702)		477.5 (253 to 702)	
Exon21L858R/neg PD-L1 TPS	163 (37 to 187)	0.0995	369 (51 to 369)	0.3317
Exon21L858R/low PD-L1 TPS	NR		NR	
Exon21L858R/high PD-L1 TPS	207.5 (104 to 311)		345 (129 to 561)	
Afatinib	137 (104 to 170)	0.4671	149.5 (129 to 170)	0.1937v
Gefitinib	311 (37 to 311)		NR	
Erlotinib	874 (51 to 874)		NR	
Osimertinib	174.5 (70 to 279)		NR	

mPFS, median progression-free survival; mOS, median overall survival; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; PD-L1, programmed death-ligand 1; CI, confidence interval; NR, not reached; TPS, tumor proportion scores.